

Matti Sällberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6634475/publications.pdf>

Version: 2024-02-01

57
papers

1,787
citations

304602

22
h-index

276775

41
g-index

58
all docs

58
docs citations

58
times ranked

2204
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Tolerance Split between Hepatitis B Virus Precore and Core Proteins. <i>Journal of Virology</i> , 2005, 79, 3016-3027.	1.5	194
2	Limited humoral immunity in hepatitis C virus infection. <i>Gastroenterology</i> , 1999, 116, 135-143.	0.6	147
3	Rapid α -amino acid-peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. <i>Immunology Letters</i> , 1991, 30, 59-68.	1.1	127
4	In Vivo Electroporation Enhances the Immunogenicity of Hepatitis C Virus Nonstructural 3/4A DNA by Increased Local DNA Uptake, Protein Expression, Inflammation, and Infiltration of CD3+ T Cells. <i>Journal of Immunology</i> , 2007, 179, 4741-4753.	0.4	123
5	Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. <i>Journal of Immunology</i> , 2020, 205, 2437-2446.	0.4	79
6	Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. <i>Journal of General Virology</i> , 2003, 84, 139-146.	1.3	74
7	Interaction of the Hepatitis B Core Antigen and the Innate Immune System. <i>Journal of Immunology</i> , 2009, 182, 6670-6681.	0.4	72
8	Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100159.	2.5	65
9	Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. <i>Hepatology</i> , 2009, 49, 1810-1820.	3.6	62
10	Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C. <i>Molecular Therapy</i> , 2013, 21, 1796-1805.	3.7	62
11	Combinatorial Approach to Hepadnavirus-Like Particle Vaccine Design. <i>Journal of Virology</i> , 2005, 79, 13656-13666.	1.5	56
12	Genetic Immunization of Chimpanzees Chronically Infected with the Hepatitis B Virus, Using a Recombinant Retroviral Vector Encoding the Hepatitis B Virus Core Antigen. <i>Human Gene Therapy</i> , 1998, 9, 1719-1729.	1.4	53
13	A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a <i>Cynomolgus macaque</i> model. <i>Nature Microbiology</i> , 2021, 6, 187-195.	5.9	49
14	In Vivo Clearance of Hepatitis C Virus Nonstructural 3/4A-Expressing Hepatocytes by DNA Vaccine-Primed Cytotoxic T Lymphocytes. <i>Journal of Infectious Diseases</i> , 2005, 192, 2112-2116.	1.9	47
15	A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2013, 208, 1008-1019.	1.9	42
16	Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 1553-1563.	3.6	35
17	The Hepatitis C Virus Non-structural NS5A Protein Impairs Both the Innate and Adaptive Hepatic Immune Response in Vivo. <i>Journal of Biological Chemistry</i> , 2009, 284, 28343-28351.	1.6	33
18	Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. <i>Journal of General Virology</i> , 2001, 82, 1299-1308.	1.3	32

#	ARTICLE	IF	CITATIONS
19	Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. <i>Vaccine</i> , 2007, 25, 1593-1606.	1.7	25
20	Electroporation for therapeutic DNA vaccination in patients. <i>Medical Microbiology and Immunology</i> , 2015, 204, 131-135.	2.6	25
21	TCR-Redirected Human T Cells Inhibit Hepatitis C Virus Replication: Hepatotoxic Potential Is Linked to Antigen Specificity and Functional Avidity. <i>Journal of Immunology</i> , 2012, 189, 4510-4519.	0.4	24
22	Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature. <i>Oncotarget</i> , 2017, 8, 4530-4542.	0.8	24
23	A Malaria Vaccine Candidate Based on a Hepatitis B Virus Core Platform. <i>Intervirology</i> , 2002, 45, 350-361.	1.2	21
24	Comparative Antigenicity and Immunogenicity of Hepadnavirus Core Proteins. <i>Journal of Virology</i> , 2005, 79, 13641-13655.	1.5	21
25	Heterologous T Cells Can Help Restore Function in Dysfunctional Hepatitis C Virus Nonstructural 3/4A-Specific T Cells during Therapeutic Vaccination. <i>Journal of Immunology</i> , 2011, 186, 5107-5118.	0.4	21
26	Hepatitis C Virus-Mediated Modulation of Cellular Immunity. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 315-329.	1.0	21
27	Evaluation of a multiple peptide assay for typing of antibodies to the hepatitis C virus: Relation to genomic typing by the polymerase chain reaction. <i>Journal of Medical Virology</i> , 1995, 45, 50-55.	2.5	20
28	Human and murine antibody recognition is focused on the ATPase/Helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein. <i>Hepatology</i> , 1998, 28, 219-224.	3.6	17
29	Improving on the Ability of Endogenous Hepatitis B Core Antigen to Prime Cytotoxic T Lymphocytes. <i>Journal of Infectious Diseases</i> , 2010, 201, 1867-1879.	1.9	17
30	DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 805-815.	1.4	16
31	Containing "The Great Houdini" of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C. <i>Drug Resistance Updates</i> , 2013, 16, 60-67.	6.5	15
32	Characterization of HLA DR13-restricted CD4+ T cell epitopes of hepatitis B core antigen associated with self-limited, acute hepatitis B. <i>Journal of General Virology</i> , 2002, 83, 3023-3033.	1.3	15
33	Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation. <i>Frontiers in Immunology</i> , 2020, 11, 552.	2.2	14
34	Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon- β production. <i>Gut</i> , 2012, 61, 589-596.	6.1	13
35	Functional Aspects of Intrahepatic Hepatitis B Virus-specific T Cells Induced by Therapeutic DNA Vaccination. <i>Molecular Therapy</i> , 2015, 23, 578-590.	3.7	13
36	Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties. <i>Journal of Virology</i> , 2017, 91, .	1.5	13

#	ARTICLE	IF	CITATIONS
37	Cleavage of the T Cell Protein Tyrosine Phosphatase by the Hepatitis C Virus Nonstructural 3/4A Protease Induces a Th1 to Th2 Shift Reversible by Ribavirin Therapy. <i>Journal of Immunology</i> , 2014, 192, 1671-1680.	0.4	12
38	Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections. <i>Journal of Infectious Diseases</i> , 2021, 223, 128-138.	1.9	10
39	Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3. <i>Journal of General Virology</i> , 2012, 93, 247-258.	1.3	10
40	A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 55-59.	1.5	9
41	A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines. <i>Vaccine</i> , 2016, 34, 2821-2833.	1.7	8
42	Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo. <i>PLoS ONE</i> , 2015, 10, e0128466.	1.1	7
43	A targeted controlled force injection of genetic material in vivo. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16016.	1.8	7
44	Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients. <i>Biochemical and Biophysical Research Communications</i> , 2013, 433, 31-35.	1.0	5
45	Prospects and progress of DNA vaccines for treating hepatitis B. <i>Expert Review of Vaccines</i> , 2016, 15, 629-640.	2.0	5
46	Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model. <i>Gut</i> , 2018, 67, 1525-1535.	6.1	5
47	Short synthetic CDR-peptides forming the antibody combining site of the monoclonal antibody against RNA bacteriophage fr neutralize the phage activity. <i>Human Antibodies</i> , 1996, 7, 106-112.	0.6	4
48	Humoral and cellular immune responses to the GB virus C/hepatitis G virus envelope 2 protein. <i>Journal of Medical Virology</i> , 2000, 62, 334-344.	2.5	4
49	A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans. <i>Genome Medicine</i> , 2009, 1, 15.	3.6	4
50	Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus. <i>Gut</i> , 2020, 69, 2203-2213.	6.1	3
51	Neonatal Exposure to Hepatitis C Virus Antigens in Uninfected Children Born to Infected Mothers. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 106-111.	0.9	2
52	Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study. <i>Journal of Neurology</i> , 2019, 266, 2208-2215.	1.8	2
53	Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 608-612.	0.9	1
54	Editorial: HBV – the naked truth?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 963-964.	1.9	1

#	ARTICLE	IF	CITATIONS
55	Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study. <i>BMJ Open</i> , 2020, 10, e035996.	0.8	1
56	Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease. <i>Journal of General Virology</i> , 2012, 93, 1680-1686.	1.3	0
57	Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses. <i>Scientific Reports</i> , 2016, 6, 24991.	1.6	0